Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUCNR1 | Q9BXA5 | 17/20 | 0.53 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.47 |
| ▸ | OXGR1 | Q96P68 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6436520 | 0.99 | SUCNR1 (0.52) | SUCNR1BDKRB1OXGR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL6425206 | 0.99 | SUCNR1 (0.52) | SUCNR1BDKRB1OXGR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL27406008 | 0.91 | SUCNR1 (0.50) | SUCNR1BDKRB1OXGR1KDM4EMEN1 | |
| SCHEMBL24194292 | 0.88 | SUCNR1 (0.49) | SUCNR1BDKRB1OXGR1ALDH1A1KDM4E | |
| SCHEMBL17921405 | 0.87 | SUCNR1 (0.48) | SUCNR1BDKRB1OXGR1ALDH1A1KDM4E | |
| SCHEMBL6265814 | 0.84 | SUCNR1 (0.53) | SUCNR1BDKRB1OXGR1ALDH1A1KDM4E | |
| SCHEMBL30471836 | 0.83 | SUCNR1 (0.57) | SUCNR1OXGR1KDM4EMEN1LMNA | |
| SCHEMBL24193793 | 0.83 | SUCNR1 (0.57) | SUCNR1OXGR1KDM4EMEN1LMNA | |
| SCHEMBL6563211 | 0.79 | SUCNR1 (0.61) | SUCNR1OXGR1KDM4EMEN1LMNA | |
| SCHEMBL20024878 | 0.78 | SUCNR1 (0.46) | SUCNR1OXGR1ALDH1A1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4159727-B1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250223289-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | SCHRODINGER, INC. | 2025-07-10 | — | — | US | disclosed |
| US-20240409927-A1 | INTEGRIN TARGETING LIGANDS FOR OCULAR DELIVERY OF RNAI COMPOUNDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-12-12 | — | — | US | disclosed |
| US-12145935-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2024-10-03 | — | — | US | disclosed |
| EP-4367246-A2 | INTEGRIN TARGETING LIGANDS FOR OCULAR DELIVERY OF RNAI COMPOUNDS | Alnylam Pharmaceuticals, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| US-20240116929-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2024-04-11 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | MORPHIC THERAPEUTIC, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-7056909-B2 | Alpha v integrin receptor antagonists | MERCK & CO., INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1040098-B1 | INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2005-04-27 | — | — | EP | disclosed |
| US-6784190-B2 | USEFUL FOR INHIBITING BONE RESORPTION, TREATING AND PREVENTING OSTEOPOROSIS, VASCULAR RESTENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIOGENESIS, TUMOR, ATHEROSCLEROSIS, INFLAMMATION, WOUND HEALING, VIRAL DISEASEDISEASE, TUMOR | MERCK & CO., INC. | 2004-08-31 | — | — | US | disclosed |
| US-20040038963-A1 | Alpha v integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2004-02-26 | — | — | US | disclosed |
| US-6410526-B1 | BONE DISORDERS; RESTENOSIS; VISION DISORDERS; ANTICHOLESTEROL AGENTS; ANTICANCER, ANTITUMOR AGENTS | MERCK & CO., INC. | 2002-06-25 | — | — | US | disclosed |
| US-20020040030-A1 | Alpha V integrin receptor antagonists | COLEMAN PAUL J (US) | 2002-04-04 | — | — | US | disclosed |
| WO-2002022616-A2 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2002-03-21 | — | — | WO | disclosed |
| US-20020010176-A1 | Integrin receptor antagonists | MERCK SHARP & DOHME CORP. | 2002-01-24 | — | — | US | disclosed |
| US-6297249-B1 | SUBSTITUTED 2-CARBOXYALKYLPYRIDINES | MERCK & CO., INC. | 2001-10-02 | — | — | US | disclosed |
| US-6048861-A | OSTEOPOROSIS; BONE DISORDERS; CARDIOVASCULAR DISORDERS; ANTIINFLAMMATROY AGENTS; WOUND HEALING AGENTS | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040030-A1 | Alpha V integrin receptor antagonists | VCAM1, ITGAV, ITGB1 | SUCNR1 143/4885BDKRB1 52/4885OXGR1 392/4885 |
| US-20240409927-A1 | INTEGRIN TARGETING LIGANDS FOR OCULAR DELIVERY OF RNAI COMPOUNDS | ITGAV, ITGA2B, ITGB2 | SUCNR1 1921/4885BDKRB1 990/4885OXGR1 2207/4885 |
| US-20240327378-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | SUCNR1 2857/4885BDKRB1 840/4885OXGR1 3160/4885 |
| US-20040038963-A1 | Alpha v integrin receptor antagonists | ITGAV, ADGRE5, ITGB3 | SUCNR1 445/4885BDKRB1 123/4885OXGR1 350/4885 |
| US-20250223289-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | SUCNR1 2582/4885BDKRB1 774/4885OXGR1 3206/4885 |
| US-12415796-B2 | Inhibitors of (αv)(β6) integrin | ITGB6, ITGA6, ITGAV | SUCNR1 2932/4885BDKRB1 1084/4885OXGR1 3445/4885 |
| US-11827621-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | SUCNR1 2837/4885BDKRB1 977/4885OXGR1 3216/4885 |
| US-12145935-B2 | Inhibitors of (α-v)(β-6) integrin | ITGB6, ITGA6, ITGAV | SUCNR1 2572/4885BDKRB1 875/4885OXGR1 3274/4885 |
| US-20240116929-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | SUCNR1 2582/4885BDKRB1 774/4885OXGR1 3206/4885 |
| US-20020010176-A1 | Integrin receptor antagonists | ITGAV, ITGB3, ADGRE5 | SUCNR1 579/4885BDKRB1 92/4885OXGR1 850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.